Price$47.15-11.06 (-19.00%)
2026-03-052026-06-08
News · 26 weeks52-78%
2025-12-142026-06-07
Mix2490d
- Insider10(42%)
- Other8(33%)
- SEC Filings4(17%)
- Leadership1(4%)
- Offering1(4%)
Latest news
25 items- INSIDERCHIEF OPERATING OFFICER Wassil Jim sold $111,416 worth of shares (2,250 units at $49.52) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 158,494 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- PRVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy AdultsFirst-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Significant Public Health Burden SAN CARLOS, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to p
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECSEC Form 10-Q filed by Vaxcyte Inc.10-Q - Vaxcyte, Inc. (0001649094) (Filer)
- SECVaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateEnrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed for VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027 Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Disease Caused by Group A Strep, in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim sold $127,870 worth of shares (2,250 units at $56.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 160,744 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form DEFA14A filed by Vaxcyte Inc.DEFA14A - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form DEF 14A filed by Vaxcyte Inc.DEF 14A - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERSEC Form 4 filed by Cowan Elvia4 - Vaxcyte, Inc. (0001649094) (Issuer)
- PRVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceSAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences
- INSIDERSEC Form 4 filed by Wassil Jim4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- PRVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerBRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of
- PRVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsOPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevnar 20® (PCV20), the Current Standard-of-Care PCVs Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Phase 3 Study Expected in Fourth Quarter of 2026 OPUS-2 Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine Designed to Provide Real-World Performance Insights in Adults; Results Expected in First Half of 2027 OPUS-3 Phase 3 Study Enrollment Ongoing in Adults Previously Vaccinated with Pneumococcal Vaccines; Results
- PRPositive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateBased on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Profile Similar to Prevnar 20® Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver Broadest-Spectrum PCV Candidates that Provide Protection Against Both Currently Circulating and Historically Preva
- INSIDERSEC Form 4 filed by Cowan Elvia4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant covered exercise/tax liability with 3,685 shares, decreasing direct ownership by 0.74% to 496,939 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSVP, Finance & CAO Cowan Elvia covered exercise/tax liability with 569 shares, was granted 10,681 shares and exercised 7,716 shares at a strike of $25.92, increasing direct ownership by 132% to 31,362 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
PCVX FAQ
7 questionsWhat does Vaxcyte Inc. do?
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020...Where does PCVX stock trade?
Vaxcyte Inc. (PCVX) is listed on NASDAQ.What sector and industry is PCVX in?
Vaxcyte Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vaxcyte Inc. go public?
Vaxcyte Inc. (PCVX) completed its IPO in 2020.What are analysts saying about PCVX?
Vaxcyte Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-01-07. Recent price targets cluster around $3800.00.What companies are similar to PCVX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PCVX side-by-side with any of them on Quantisnow.How can I track PCVX on Quantisnow?
Quantisnow aggregates Vaxcyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCVX to receive live email and push alerts on every new disclosure.